Literature DB >> 22415641

Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions.

Christopher B Fox1, Susan L Baldwin, Malcolm S Duthie, Steven G Reed, Thomas S Vedvick.   

Abstract

Egg phosphatidylcholine is commonly used as an emulsifier in formulations administered parenterally. However, synthetic phosphatidylcholine (PC) emulsifiers are now widely available and may be desirable substitutes for egg-derived phospholipids due to stability, purity, and material source considerations. In earlier work, we demonstrated that a squalene-1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) emulsion provided equivalent physical stability compared to a squalene-egg PC emulsion. In the present manuscript, we evaluate the physical stability of vaccine adjuvant emulsions containing a range of other synthetic phosphatidylcholine emulsifiers. Besides the POPC emulsion, the 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) emulsion showed good particle size and visual stability compared to emulsions made with other synthetic phospholipids. Moreover, comparable immune responses were elicited by squalene emulsions employing various synthetic PC or egg PC emulsifiers in combination with an inactivated influenza vaccine or a recombinant malaria antigen, and these responses were generally enhanced compared to antigen without adjuvant. Therefore, we show that (1) some synthetic PCs (DMPC, POPC, and to a lesser extent 1,2-dioleoyl-sn-glycero-3-phosphocholine) are effective stabilizers of squalene emulsion over a range of storage temperatures while others are not (1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, and 1,2-dilauroyl-sn-glycero-3-phosphocholine) and (2) the immunogenicity of stable squalene emulsions is similar regardless of PC source.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22415641      PMCID: PMC3364393          DOI: 10.1208/s12249-012-9771-x

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  25 in total

1.  Half-dose influenza vaccine: stretching the supply or wasting it?

Authors:  Ann R Falsey
Journal:  Arch Intern Med       Date:  2008-12-08

2.  MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).

Authors:  Barbara C Baudner; Vanessa Ronconi; Daniele Casini; Marco Tortoli; Jina Kazzaz; Manmohan Singh; Lynn D Hawkins; Andreas Wack; Derek T O'Hagan
Journal:  Pharm Res       Date:  2009-03-03       Impact factor: 4.200

3.  Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.

Authors:  Susan L Baldwin; Narek Shaverdian; Yasuyuki Goto; Malcolm S Duthie; Vanitha S Raman; Tara Evers; Farah Mompoint; Thomas S Vedvick; Sylvie Bertholet; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2009-08-11       Impact factor: 3.641

4.  Interfacial properties as stability predictors of lecithin-stabilized perfluorocarbon emulsions.

Authors:  J K Yoon; D J Burgess
Journal:  Pharm Dev Technol       Date:  1996-12       Impact factor: 3.133

5.  A novel assay to determine the hemolytic activity of drugs incorporated in colloidal carrier systems.

Authors:  T K Bock; B W Müller
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

6.  Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Authors:  Christopher B Fox; Susan L Baldwin; Malcolm S Duthie; Steven G Reed; Thomas S Vedvick
Journal:  Vaccine       Date:  2011-09-09       Impact factor: 3.641

7.  Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions.

Authors:  Christopher B Fox; Susan Lin; Sandra J Sivananthan; Timothy S Dutill; Kristen T Forseth; Steven G Reed; Thomas S Vedvick
Journal:  Pharm Dev Technol       Date:  2010-06-16       Impact factor: 3.133

8.  Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.

Authors:  Steven A Rosenberg; James C Yang; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Susan L Schwarz; Kathleen E Morton; Carolyn M Laurencot; Richard M Sherry
Journal:  J Immunother       Date:  2010 Jul-Aug       Impact factor: 4.456

9.  Phospholipids as Emulsion Stabilizers

Authors: 
Journal:  J Colloid Interface Sci       Date:  1996-12-01       Impact factor: 8.128

10.  Degradation of kinetically-stable o/w emulsions.

Authors:  Ignác Capek
Journal:  Adv Colloid Interface Sci       Date:  2004-03-19       Impact factor: 12.984

View more
  8 in total

1.  Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.

Authors:  Christopher B Fox; Susan L Baldwin; Thomas S Vedvick; Evelina Angov; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2012-08-15

2.  Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Authors:  Christopher B Fox; Susan L Baldwin; Malcolm S Duthie; Steven G Reed; Thomas S Vedvick
Journal:  Vaccine       Date:  2011-09-09       Impact factor: 3.641

3.  Evaluating the efficacy of extracted squalene from seed oil in the form of microemulsion for the treatment of COVID-19: A clinical study.

Authors:  Mahmoud Ebrahimi; Nafiseh Farhadian; Ali Reza Amiri; Fatemeh Hataminia; Sara Saffar Soflaei; Mohammad Karimi
Journal:  J Med Virol       Date:  2021-08-26       Impact factor: 20.693

4.  Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.

Authors:  Janny Westdijk; Patrick Koedam; Mario Barro; Benjamin P Steil; Nicolas Collin; Thomas S Vedvick; Wilfried A M Bakker; Peter van der Ley; Gideon Kersten
Journal:  Vaccine       Date:  2013-01-09       Impact factor: 3.641

5.  Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses.

Authors:  Emilie Seydoux; Hong Liang; Natasha Dubois Cauwelaert; Michelle Archer; Nicholas D Rintala; Ryan Kramer; Darrick Carter; Christopher B Fox; Mark T Orr
Journal:  J Immunol       Date:  2018-05-16       Impact factor: 5.422

6.  Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy.

Authors:  Christopher B Fox; Lucien Barnes V; Tara Evers; James D Chesko; Thomas S Vedvick; Rhea N Coler; Steven G Reed; Susan L Baldwin
Journal:  Influenza Other Respir Viruses       Date:  2012-11-05       Impact factor: 4.380

7.  Enhancement of immunomodulative effect of lactic acid bacteria on plasmacytoid dendritic cells with sucrose palmitate.

Authors:  Masaya Kanayama; Yukiko Kato; Toshikazu Tsuji; Yuki Konoeda; Akiko Hashimoto; Osamu Kanauchi; Toshio Fujii; Daisuke Fujiwara
Journal:  Sci Rep       Date:  2018-02-16       Impact factor: 4.379

8.  Squalene Emulsion Manufacturing Process Scale-Up for Enhanced Global Pandemic Response.

Authors:  Tony Phan; Christian Devine; Erik D Laursen; Adrian Simpson; Aaron Kahn; Amit P Khandhar; Steven Mesite; Brad Besse; Ken J Mabery; Elizabeth I Flanagan; Christopher B Fox
Journal:  Pharmaceuticals (Basel)       Date:  2020-07-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.